The Food and Drug Administration has recently released new provider information to assist in prescribing Paxlovid for treatment of mild to moderate COVID-19. The AMA is sharing this information at the request of the FDA Commissioner to assist in increasing use of Paxlovid for treatment of COVID-19 positive patients. The information provides clarity around patient eligibility for Paxlovid and includes a patient eligibility screening checklist for use by prescribers. It also includes guidance on managing drug-drug interactions with Paxlovid.
Additionally, the FDA is hosting a stakeholder call for provider organizations on Friday, May 6th at 1:00pm EDT. The webinar will be available at the link below and will include open Q&A time for any questions on use of Paxlovid.
Paxlovid Stakeholder Call – May 6, 2022
Please join the FDA’s Center for Drug Evaluation and Research for a stakeholder call about Paxlovid. Paxlovid is an authorized oral treatment for certain patients with mild to moderate COVID-19 who are at high risk of progression to severe COVID-19, including hospitalization or death. The call will feature Dr. John Farley, MD, the director of Office of Infectious Diseases, Office of New Drugs, in the Center for Drug Evaluation and Research.
Paxlovid Stakeholder Call Agenda
May 6, 2022 – 1:00pm-1:30pm ET
- Opening Remarks (FDA)
- Prescriber Checklist & Drug Interaction Table (FDA)
- Live Q&A (Stakeholder Groups and FDA)
- Closing Remarks (FDA)
Join by Telephone:
Dial: 1 669 254 5252
Meeting ID: 161 178 6251
One tap mobile: